Immunic, Inc.IMUXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
-6.35%
↓ 107% below average
Average (39q)
87.64%
Historical baseline
Range
High:2370.00%
Low:-99.67%
CAGR
-3.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -6.35% |
| Q2 2025 | -0.76% |
| Q1 2025 | -0.39% |
| Q4 2024 | 1.16% |
| Q3 2024 | 16.63% |
| Q2 2024 | -2.20% |
| Q1 2024 | -2.84% |
| Q4 2023 | -2.59% |
| Q3 2023 | -6.50% |
| Q2 2023 | -7.80% |
| Q1 2023 | 10.75% |
| Q4 2022 | 25.39% |
| Q3 2022 | -0.01% |
| Q2 2022 | -5.20% |
| Q1 2022 | -5.08% |
| Q4 2021 | 18.72% |
| Q3 2021 | -1.64% |
| Q2 2021 | 36.63% |
| Q1 2021 | 3.07% |
| Q4 2020 | 1.23% |
| Q3 2020 | 10.54% |
| Q2 2020 | 55.22% |
| Q1 2020 | 6.77% |
| Q4 2019 | -15.15% |
| Q3 2019 | 17.80% |
| Q2 2019 | 1120.45% |
| Q1 2019 | 2370.00% |
| Q4 2018 | -99.67% |
| Q3 2018 | -30.84% |
| Q2 2018 | -14.74% |
| Q1 2018 | -0.32% |
| Q4 2017 | 5.17% |
| Q3 2017 | -1.47% |
| Q2 2017 | 2.14% |
| Q1 2017 | 8.64% |
| Q4 2016 | 18.65% |
| Q3 2016 | 8.91% |
| Q2 2016 | 0.01% |
| Q1 2016 | 0.41% |
| Q4 2015 | -29.20% |